MYC and neoplasm: Finally, both immunoblotting and immunostaining results revealed that MRTX849 monotherapy inhibited ERK phosphorylation in all the aforementioned mouse models, but no obvious decrease of c-Myc in the KRASG12Ci-resistant xenograft tumors (Fig. 4J, K), indicating that the alteration of c-Myc level could be helpful for predicting tumor responses to KRASG12Ci treatment.